ERBB2 and ovarian cancer: HER2 is not only overexpressed in 20-30% of breast cancer, but also found in lung cancer, liver cancer, ovarian cancer and other cancers (19–23), and can be used as targets for targeted cancer treatment of most malignant cancers.